Valuation: Abbott Laboratories (Pakistan) Limited

Market Cap 90.82B 328M 293M 271M 245M 459M 31.17B 467M 3.26B 1.29B 16.33B 1.23B 1.21B 51.48B P/E 2024
23.2x
P/E 2025 -
Enterprise Value 90.82B 328M 293M 271M 245M 459M 31.17B 467M 3.26B 1.29B 16.33B 1.23B 1.21B 51.48B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
19.95%
Yield 2024 *
-
Yield 2025 3.81%
1 day+0.03%
1 week-1.77%
Current month+1.12%
1 month+0.27%
3 months+0.96%
6 months+0.81%
Current year-11.66%
1 week 924
Extreme 924
952.42
1 month 900
Extreme 900
952.42
Current year 821
Extreme 821
1,274
1 year 821
Extreme 821
1,274
3 years 382.56
Extreme 382.56
1,310
5 years 330
Extreme 330
1,310
10 years 302.1
Extreme 302.1
1,310
Manager TitleAgeSince
Chief Executive Officer - 01/04/2016
Director of Finance/CFO - 01/11/2019
Chief Operating Officer - 01/06/2024
Director TitleAgeSince
Chairman - 30/05/2022
Director/Board Member - 01/03/2009
Director/Board Member - 04/06/2014
Change 5-day change 1-year change 3-year change Capi.($)
+0.03%-1.77%-22.66%+131.26% 328M
-2.54%+1.31%+54.27%+114.96% 1,135B
-1.42%+3.23%+38.56%+74.44% 635B
+0.16%+0.08%+25.29%+95.23% 505B
-0.31%+3.09%+44.14%+64.80% 378B
-1.34%-0.47%+66.04%+41.00% 358B
-0.68%+2.65%+22.98%+50.39% 295B
-1.20%+3.04%+2.33%+22.86% 266B
-1.79%+1.57%+50.56%+59.08% 237B
-0.73%-0.10%+29.02%+99.67% 193B
Average -0.98%+1.74%+31.05%+75.37% 400.4B
Weighted average by Cap. -1.35%+2.66%+41.02%+79.76%

Financials

2024 2025
Net sales 68.18B 246M 220M 203M 184M 345M 23.4B 350M 2.45B 969M 12.26B 925M 905M 38.65B 75.4B 273M 243M 225M 204M 381M 25.88B 388M 2.71B 1.07B 13.56B 1.02B 1B 42.74B
Net income 5.23B 18.92M 16.9M 15.61M 14.15M 26.47M 1.8B 26.9M 188M 74.37M 941M 71.02M 69.51M 2.97B 7.97B 28.8M 25.72M 23.76M 21.53M 40.28M 2.73B 40.95M 286M 113M 1.43B 108M 106M 4.52B
Net Debt - -
Projected Income Statement - Annual - Abbott Laboratories (Pakistan) Limited
Logo Abbott Laboratories (Pakistan) Limited
Abbott Laboratories Pakistan Limited is engaged in the manufacture, import and marketing of branded generic pharmaceutical, nutritional, diagnostic, diabetes care, molecular devices, hospital, and consumer products. The Company operates through four segments: Pharmaceutical, Nutritional, Diagnostic, and Others. It offers treatment options for a number of areas, including the digestive system, heart health, women’s health, respiratory illness, central nervous system/pain and influenza vaccines. Its nutritional brands include Similac, PediaSure, Pedialyte, Ensure, and Glucerna. It offers tests and diagnostic tools, medical diagnostic instruments, automation and informatics solutions for hospitals, reference labs, blood centers, emergency departments, physician offices and clinics. The Company’s easy-to-use test strips require only tiny blood samples while its meters provide results and reports.
Employees
1,380
Date Price Change Volume
23/10/26 PKR 927.67 +0.03% 28,777
22/10/26 PKR 927.37 -1.52% 3,686
21/10/26 PKR 941.66 +0.65% 11,271
20/10/26 PKR 935.61 -1.28% 2,011
19/10/26 PKR 947.72 +0.35% 3,295
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Abbott Laboratories (Pakistan) Limited
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
927.67
Average target price
-

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Abbott Laboratories (Pakistan) Limited
  1. Stock Market
  2. Stocks
  3. ABOT Stock